hepatic fibrosis with cholangitis component. At this moment, the patient is doing well and is has not been treated with any specific medication for congenital hepatic fibrosis.
DISCUSSION
Congenital hepatic fibrosis (CHF) is an autosomal recessive disease (1, 2) , due to a mutation on PKHD1, a gene encoding fibrocystin/ polyductine (1, 2, 3) , a ciliary protein expressed in cholangiocytes. CHF is defined by varying degrees of periportal fibrosis and irregular proliferation of bile ducts (1, 4, 5) , being part of the so-called Fibropolycystic Diseases, which also include Caroli's Disease (6) , Autosomal Dominant Renal Disease, Autosomal Recessive Polycystic Kidney Disease, Von Meyenburg Complex (bile duct hamartoma), and choledochal cyst (5, 7, 8) . Typically, CHF patients have been diagnosed in infancy or early childhood, but some recent data demonstrate that some patients remain asymptomatic for long periods (4) , as the presented case here. The incidence and prevalence of CHF are not exactly known, but it is known to be a rare disease, with only a few hundred cases described in the literature (9) . The prevalence of congenital hepatic fibrosis in portal hypertensive children in a study from north India was 3% (7) . It is estimated that, when CHF occurs with Autosomal Recessive Polycystic Kidney Disease, the frequency is 1 in 20,000 live births, affecting all ethnic groups (8) . The disease may occur associated with other hereditary and nonhereditary diseases, with the most frequent associations being: Joubert Syndrome and Bardet-Biedl Syndrome (10) . The potential for involving several organs, requiring several medical specialties in differential diagnosis and treatment, reinforces the importance of this review article.
A B
C D E F FIGURE 3. Anatomopathological examination. A) the hematoxy lin-eosin staining shows the irregular contours of the various bile ducts, indicating ductal plaque remodeling disorders (he, original x100). B) mixed inflammatory infiltrate, variable in the portal spaces, is moderate in this figure, surrounding or even permeating the ductal epithelium (he, original x200). C) the immunohistochemical reactions for the detection of actin in the vessel wall demonstrate the obliteration of the portal vein branch, which is surrounded by several small venous branches (ihc, ac 1 to 4, original x100). 
A B C Pathophysiology CHF is a genetic cholangiopathy caused by mutations in PKHD1, the gene located on chromosome 6p21-23 (11) , which encodes fibrocystin/polyductine (FPC), a protein of yet unknown function, expressed in the cilia and centromers of the bile ducts and renal tubule cells (2) . In others chronic hepatobiliary diseases, progression to fibrosis is due to a repair response against necroinflammatory damage in hepatocytes and/or cholangiocytes. In CHF, the essential pathological processes appear to be genetically based, leading to ductal plate malformation, possibly beginning with maturation arrest and lack of ductal plate remodeling (7) . The ductal plate is an embryological structure formed by a cylindrical layer of epithelial cells that involve a branch of the portal vein (1) and is the embryological precursor of intrahepatic bile ducts (12) . As a result of this defect in remodeling the ductal plate, a persistence of immature embryological ductile structures occurs, which lead to the formation of portal fibrosis tissues. This portal fibrosis would ultimately lead to recurrent cholangitis or portal hypertension and associated symptoms (1) . Interestingly, our reported patient had no history of symptoms and complications at the time of diagnosis.
Although it is well established that chronic portal hypertension can lead to portal vein thrombosis with eventual cavernomatous transformation (CTPV) (13) , it is believed that in the case of the CHF the lesions of the portal vein branches are a component of the disease, present from the beginning. The main support for this theory is based on the embryological relationship of the hepatic vessels and ducts (12) . Malformation of the ductal plate has a strong association with malformation of the portal vein, resulting in excessive small and branched branches of the portal vein (1, 14) . A study from Barayktar et al. showed that almost 50% of CHF patients present CTPV and that patients with CTPV presented more prominent splenomegaly and a greater chance of varicose digestive hemorrhage (15) . Our patient also had no signs of CTPV. The maturation stage of the ductal plate arrest would determine the final disease: either it involves the small interlobular bile ducts leading to CHF or involves the middle intrahepatic bile ducts causing Caroli's Disease (5) . The occurrence of simultaneous involvement of the two types of bile ducts (small and medium) results in Caroli Syndrome (FHC associated with Caroli Disease). In these cases, the clinic of Caroli's disease (recurrent cholangitis episodes) will be predominant, with CHF often underdiagnosed. Thus, hepatic biopsy becomes essential for differential diagnosis between Caroli's Disease or Syndrome (1) . In a more recent study, Locatelli et al. described that FPC deficiency would lead to the formation of microhamartomas and segmental dilations of the bile ducts with portal hypertension. Other studies have also identified various defects in intracellular signaling of FPC-deficient cells, including increased adenosine cyclic monophosphate (cAMP)/protein kinase A signaling and activation of β-catenin-dependent protein kinase A (16) . This, in turn, has appeared as a new regulator of inflammation, capable of influencing secretion of cytokines in liver cancer in experimental models. Hence, it has been proposed that persistent and unresolved cellular dysfunction may promote a chronic and low-grade inflammatory response and may lead to scarring (called "parainflammation") (2) . In this same study, the author showed evidence that this chronic and mild inflammatory response, generated by FPC-deficient cholangiocytes, secretes chemokines capable of recruiting macrophages derived from bone marrow, and responds to them through the activation of αvβ6 integrin, a local activator of TGFβ1. This theory proposes a new paradigm of biliary fibrosis and would be a model for understanding the relationship between cellular dysfunction, inflammation, hepatic fibrosis and macrophage polarization over time. This theory, however, contradicts the previously mentioned that the process of hepatic fibrosis in the CHF would occur without the presence of chronic inflammation.
Other authors have demonstrated and established that TGFβ is a potent growth inhibitory factor and a pro-fibrotic cytokine, with a central role in the physiological healing process as well as in the pathogenesis of organ fibrosis. The onset of activation of hepatic stellate cells (which are also at the center of the liver fibrosis process) (17, 18) is primarily induced by TGFβ1 derived from Kupfer cells (1) . TGFβ1 would mediate its pro-fibrotic action through stimulation of fibroblasts and related cell types, including stellate cells, to secrete various extracellular matrix proteins (19) . Therefore, in pathological situations would lead to the accumulation of fibrotic matrix and in physiological situations would lead to efficient wound healing (1) . There are other studies that intend to establish the pathophysiological mechanism behind this abnormal and excessive fibrotic response associated with CHF, in which the possible involved ones would be plasminogen and tissue plasminogen activator (tPA), osteopontin and microRNA (1, 20) .
Clinical course
The onset of presentation and severity of symptoms is very variable. The majority manifests even in childhood (7, 21) . In most patients, the first manifestations of the disease are signs and symptoms related to portal hypertension, often with gastrointestinal bleeding (5) . Hemathemesis and melena are initial symptoms in 30%-70% of cases (9) . More rarely, they may present episodes of cholangitis. Depending on the associated diseases, patients will have signs and symptoms related to other organs such as kidneys and central nervous system (CNS) (1) . These patients classically do not have cirrhosis, maintain normal hepatic lobular architecture and liver function (21) . CHF is classified into 4 types (5, 7, 9) : 1) Portal hypertension 2) Cholestatic / Cholangitis 3) Mixed 4) Latent The reported case probably has the latent form. The portal hypertension type of CHF is the most common and becomes more severe in the presence of portal vein abnormality. Latent type presents in old age or is an incidental finding, as do our case. On physical examination the patient may present with hepatomegaly, especially of the left lobe, splenomegaly and nephromegaly. The liver is firm in consistency and has a slightly nodular surface. In laboratory tests, there is a slight elevation of liver enzymes, where in cholestatic conditions predominate elevations in alkaline phosphatase, gamma-glutamyltransferase and bilirubin. Cytopenias may occur as a consequence of splenomegaly and this is probably the cause of low levels of platelets in our patient. Changes in renal function tests occur when there is CHF associated with extensive cystic kidney disease, which may progress to end-stage renal failure. When kidney and liver disease are combined, the severity of each is independent (3) .
Diagnosis
Ultrasound is usually the first method employed due to availability, low cost and harmlessness. It is able to detect alterations in the bile ducts and hepatic parenchyma, besides renal alterations. The most common findings are hypertrophy of the left lateral and caudate hepatic segments, right segment atrophy, splenomegaly, intra-and extrahepatic biliary dilation with concomitant cystic and solid lesions (regeneration nodules), periportal thickening, hepatic and renal cysts, and CTPV.
Computed tomography (CT) has advantages over ultrasound by better morphological representation, with accurate volumetric measurements, as well as by adequately showing the vessels and biliary tree. However, nuclear magnetic resonance imaging (MRI) with cholangioresonance is an important diagnostic alternative because it does not expose the patient to radiation and allows a very detailed evaluation of the biliary tree.
Anatomopathological examination, interpreted in the clinicalradiological context, is of great importance for a diagnostic definition of CHF. It is possible various degrees of fibrosis with nodular formations, and when diagnosed late, clinical and even histological findings may be confused with liver cirrhosis (1) . In addition, large fibrous bands are seen in the portal tract, with an increased number of proliferated irregular bile ducts with normal cubic epithelium. These findings were seen in our patient's liver biopsy, supporting the diagnosis. Hepatic lobes are normal with hepatocytes of usual morphology, especially in the early stages of the disease.
Among the major complications, signs of cholestasis and even recurrent cholangitis can be seen. The development of cholangiocarcinoma is another possible complication. When CHF is associated with Caroli's disease, cholangiocarcinoma occurs in 2.5%-16% of cases (1) . On the other hand, in cases of isolated CHF, there are few reports of cholangiocarcinoma (22, 23) . It is suggested that malignant transformation via dysplasia occurs in abnormal intrahepatic bile trees in older patients with CHF (23) . There are also some cases of hepatocellular carcinoma associated with CHF reported in the literature (21) .
Treatment
To date, there is no specific therapy capable of stopping or reversing the pathological process in CHF (1, 18) . When considering the antifibrotic treatment, it is necessary to remember that fibrosis is a dynamic process in which the degradation of the extracellular matrix, and not only the matrix formation, is important (18) . Moreover, many studies in the literature emphasize that liver fibrosis is a reversible process (24) . Different researchers try to find a drug that can control the progression of the disease, stopping and even reversing fibrosis. Some drugs have shown success in animal studies (18) , but have failed to present benefits in humans, including colchicine, angiotensin II blocker, interferon gamma and pirfenidone (1, 18, 24, 25) . Therefore, the therapeutic strategy for CHF, so far, is to treat the complications of the disease (5) . Endoscopy is an important option for primary and secondary prophylaxis of bleeding esophageal and gastric varices, as well as for treatment of acute bleeding (26) . Likewise, it plays an important role in the management of recurrent cholangitis (especially in Caroli syndrome) (1, 5) . Transjugular portosystemic intrahepatic shunt (TIPS) is indicated in cases not eligible for endoscopic sclerotherapy and also in cases of refractory upper gastrointestinal bleeding, such as a bridge to liver transplantation.
Surgical shunts for portal decompression are indicated in cases of upper gastrointestinal bleeding not amenable to upper endoscopy. In cases of CHF associated with Caroli's disease with recurrent cholangitis, partial hepatic resection may be indicated in cases of extensive heterogeneous involvement (1, 5) . Hepatic transplantation is the only curative treatment for CHF. It is indicated in the advanced stages of the disease, with development of hepatic insufficiency, or in cases of recurrent cholangitis or malignant transformation (27) . The vast majority of cases of CHF who underwent liver transplantation, described in the literature, had Caroli's disease associated with recurrent cholangitis. On the other hand, Geramizadeh et al., in 2010, reported two cases of CHF patients who required hepatic transplantation due to hepatic insufficiency, without previous or current history of cholangitis (4) . In cases of associated renal and hepatic diseases, combined kidney and liver transplantation may be necessary. In addition, one study showed that in patients with liver and kidney disease who underwent only liver transplantation, there was an improvement in renal function (28) .
CONCLUSION
The case reported herein corresponds to a form that is practically asymptomatic, but has a well-defined histological pattern of Congenital Hepatic Fibrosis (CHF), a rare or rarely diagnosed disease. The clinical spectrum of the CHF is very broad, and it can affect several organs, being a disease to be considered associated with other conditions, especially the kidney fibropolycystic disease.
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